Experimental evidence shows indirect-pathway d2 receptors drive dyskinesia in L-DOPA treatment, implying new insights for therapy.
We provide experimental evidence that indirect-pathway D2 receptors significantly contribute to the expression of dyskinesia during L-DOPA treatment and mediate D2 agonist-dependent dystonic features.
No takes yet. Share an insight, caveat, or question.
Andreoli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: